{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:38:40Z","timestamp":1790829520666,"version":"4.1.0"},"reference-count":274,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR160047"],"award-info":[{"award-number":["RR160047"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["1842494"],"award-info":[{"award-number":["1842494"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["1R01DK120459-01"],"award-info":[{"award-number":["1R01DK120459-01"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["RR160047"],"award-info":[{"award-number":["RR160047"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1842494"],"award-info":[{"award-number":["1842494"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1R01DK120459-01"],"award-info":[{"award-number":["1R01DK120459-01"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RR160047"],"award-info":[{"award-number":["RR160047"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1842494"],"award-info":[{"award-number":["1842494"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01DK120459-01"],"award-info":[{"award-number":["1R01DK120459-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.addr.2021.113896","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T03:55:05Z","timestamp":1627358105000},"page":"113896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Clinical translation of immunomodulatory therapeutics"],"prefix":"10.1016","volume":"176","author":[{"given":"Amanda","family":"Nash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Aghlara-Fotovat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Scull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Veiseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2021.113896_b0005","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2021.113896_b0010","first-page":"96","article-title":"Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.addr.2021.113896_b0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-015-0536-1","article-title":"Daratumumab: First Global Approval","volume":"76","author":"McKeage","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2021.113896_b0020","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia","volume":"25","author":"O'Leary","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2021.113896_b0025","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14712598.2021.1889510","article-title":"Brexucabtagene autoleucel for the treatment of relapsed\/refractory mantle cell lymphoma","volume":"21","author":"Mian","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.addr.2021.113896_b0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40263-018-0488-6","article-title":"Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010","volume":"32","author":"Faissner","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.addr.2021.113896_b0035","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.3748\/wjg.v24.i23.2457","article-title":"Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence","volume":"24","author":"Scribano","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.addr.2021.113896_b0040","doi-asserted-by":"crossref","unstructured":"P. Mulero, L. Midaglia, X. Montalban, Ocrelizumab: a new milestone in multiple sclerosis therapy, Ther Adv Neurol Disord, 11 (2018) 1756286418773025.","DOI":"10.1177\/1756286418773025"},{"key":"10.1016\/j.addr.2021.113896_b0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1759720X17752037","article-title":"Efficacy and safety of sarilumab in patients with active rheumatoid arthritis","volume":"10","author":"McCarty","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.addr.2021.113896_b0050","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/1744666X.2018.1532291","article-title":"Tofacitinib for the treatment of ulcerative colitis","volume":"14","author":"Fernandez-Clotet","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.addr.2021.113896_b0055","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-020-00938-z","article-title":"Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment","volume":"43","author":"Veeravalli","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.addr.2021.113896_b0060","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMp1110327","article-title":"Learning about the safety of drugs\u2013a half-century of evolution","volume":"365","author":"Avorn","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2021.113896_b0065","unstructured":"Cancer Research Institute, Immunomodulators: Checkpoint Inhibitors, Cytokines, Agonists, and Adjuvants, 2020."},{"key":"10.1016\/j.addr.2021.113896_b0070","unstructured":"U.S. Food & Drug Administration, Approved Cellular and Gene Therapy Products, 2021."},{"key":"10.1016\/j.addr.2021.113896_b0075","unstructured":"U.S. Food & Drug Administration, Vaccines Licensed for Use in the United States, 2021."},{"key":"10.1016\/j.addr.2021.113896_b0080","unstructured":"The Antibody Society, Antibody therapeutics approved or in regulatory review in the EU or US, 2021."},{"key":"10.1016\/j.addr.2021.113896_b0085","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.addr.2021.113896_b0090","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.1016\/j.jaci.2009.08.018","article-title":"Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins","volume":"125","author":"Lee","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.addr.2021.113896_b0095","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1042\/EBC20160017","article-title":"The immune system","volume":"60","author":"Nicholson","year":"2016","journal-title":"Essays Biochem"},{"key":"10.1016\/j.addr.2021.113896_b0100","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jaci.2009.12.980","article-title":"Overview of the immune response","volume":"125","author":"Chaplin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.addr.2021.113896_b0105","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1172\/JCI10026","article-title":"Immunomodulation of cancer: potential use of selectively replicating agents","volume":"105","author":"Agha-Mohammadi","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.addr.2021.113896_b0110","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/annrheumdis-2020-218019","article-title":"Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs","volume":"79","author":"Isaacs","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.addr.2021.113896_b0115","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.4317\/medoral.19087","article-title":"Immunomodulatory drugs: oral and systemic adverse effects","volume":"19","author":"Bascones-Martinez","year":"2014","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.addr.2021.113896_b0120","first-page":"240","article-title":"Development of new immunotherapy treatments in different cancer types","volume":"9","author":"Stanculeanu","year":"2016","journal-title":"J Med Life"},{"key":"10.1016\/j.addr.2021.113896_b0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.addr.2021.113896_b0130","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.4161\/21645515.2014.980707","article-title":"Vaccines versus immunotherapy: overview of approaches in deciding between options","volume":"10","author":"Dalgleish","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.addr.2021.113896_b0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-018-0278-1","article-title":"An introduction to immunology and immunopathology","volume":"14","author":"Marshall","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.addr.2021.113896_b0140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/01.RES.0000029784.15893.10","article-title":"Innate and adaptive immunity in the pathogenesis of atherosclerosis","volume":"91","author":"Hansson","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.addr.2021.113896_b0145","first-page":"20143085","article-title":"Evolution of the immune system in humans from infancy to old age","volume":"282","author":"Simon","year":"2015","journal-title":"Proc Biol Sci"},{"key":"10.1016\/j.addr.2021.113896_b0150","doi-asserted-by":"crossref","first-page":"F47","DOI":"10.1084\/jem.193.12.F47","article-title":"On the role of the innate immunity in autoimmune disease","volume":"193","author":"Bachmann","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.addr.2021.113896_b0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40487-015-0015-6","article-title":"Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer","volume":"4","author":"Adjiri","year":"2016","journal-title":"Oncol Ther"},{"key":"10.1016\/j.addr.2021.113896_b0160","article-title":"Squamous Cell Carcinoma: An Update on Diagnosis and Treatment","volume":"10","author":"Combalia","year":"2020","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.addr.2021.113896_b0165","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/cncr.31551","article-title":"Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics","volume":"124","author":"Cronin","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2021.113896_b0170","first-page":"370","article-title":"Advanced pancreatic cancer: The standard of care and new opportunities","volume":"12","author":"Mohammad","year":"2018","journal-title":"Oncol Rev"},{"key":"10.1016\/j.addr.2021.113896_b0175","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0180","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/tcrm.2007.3.2.341","article-title":"Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)","volume":"3","author":"Le Tourneau","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.addr.2021.113896_b0185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12094-017-1765-4","article-title":"SEOM clinical guideline for treatment of kidney cancer","volume":"20","author":"Gallardo","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1756287215614236","article-title":"Pazopanib in the treatment of advanced renal cell carcinoma","volume":"8","author":"Cella","year":"2016","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.addr.2021.113896_b0195","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00018-018-2954-1","article-title":"Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells","volume":"76","author":"Mikula-Pietrasik","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.addr.2021.113896_b0200","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/IJWH.S7012","article-title":"Clinical trials and progress with paclitaxel in ovarian cancer","volume":"2","author":"Kumar","year":"2010","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.addr.2021.113896_b0205","first-page":"17","article-title":"Ovarian cancer standard of care: are there real alternatives?, Chin","volume":"34","author":"Della Pepa","year":"2015","journal-title":"J Cancer"},{"key":"10.1016\/j.addr.2021.113896_b0210","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fphar.2018.00245","article-title":"Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?","volume":"9","author":"Nurgali","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.addr.2021.113896_b0215","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/pbc.21835","article-title":"Potential chemotherapy side effects: what do oncologists tell parents?","volume":"52","author":"Ramirez","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.addr.2021.113896_b0220","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S1470-2045(07)70140-7","article-title":"Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed?","volume":"8","author":"Bockhorn","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0225","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw0726","article-title":"RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues","volume":"364","author":"Yizhak","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.113896_b0230","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0235","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2021.113896_b0240","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2021.113896_b0245","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2021.113896_b0250","doi-asserted-by":"crossref","unstructured":"M. Kalos, B.L. Levine, D.L. Porter, S. Katz, S.A. Grupp, A. Bagg, C.H. June, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3 (2011) 95ra73.","DOI":"10.1126\/scitranslmed.3002842"},{"key":"10.1016\/j.addr.2021.113896_b0255","doi-asserted-by":"crossref","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.addr.2021.113896_b0260","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-15-0600","article-title":"FDA Approval Summary: Ramucirumab for Gastric Cancer","volume":"21","author":"Casak","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2021.113896_b0265","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-015-0522-7","article-title":"Talimogene Laherparepvec: First Global Approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2021.113896_b0270","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s40265-016-0618-8","article-title":"Atezolizumab: First Global Approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2021.113896_b0275","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40265-016-0680-2","article-title":"Olaratumab: First Global Approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2021.113896_b0280","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2021.113896_b0285","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s40265-018-1012-5","article-title":"Cemiplimab: First Global Approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2021.113896_b0290","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: First Approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2021.113896_b0295","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.addr.2021.113896_b0300","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/0961203308090020","article-title":"The innate immune system in SLE: type I interferons and dendritic cells","volume":"17","author":"Ronnblom","year":"2008","journal-title":"Lupus"},{"issue":"Suppl 5","key":"10.1016\/j.addr.2021.113896_b0305","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1289\/ehp.99107s5661","article-title":"Introduction to immunology and autoimmunity","volume":"107","author":"Smith","year":"1999","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.addr.2021.113896_b0310","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2613.2006.00507.x","article-title":"Chronic inflammation: a failure of resolution?","volume":"88","author":"Lawrence","year":"2007","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.addr.2021.113896_b0315","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.autrev.2008.12.019","article-title":"The role of innate immune responses in autoimmune disease development","volume":"8","author":"Waldner","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.addr.2021.113896_b0320","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.addr.2021.113896_b0325","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1042\/cs0940557","article-title":"Anti-inflammatory actions of glucocorticoids: molecular mechanisms","volume":"94","author":"Barnes","year":"1998","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.addr.2021.113896_b0330","doi-asserted-by":"crossref","unstructured":"K.G. Blumenthal, K.H. Lai, M. Huang, Z.S. Wallace, P.G. Wickner, L. Zhou, Adverse and Hypersensitivity Reactions to Prescription Nonsteroidal Anti-Inflammatory Agents in a Large Health Care System, J Allergy Clin Immunol Pract, 5 (2017) 737-743 e733.","DOI":"10.1016\/j.jaip.2016.12.006"},{"key":"10.1016\/j.addr.2021.113896_b0335","first-page":"1143","article-title":"Effect of tenoxicam on inflammation and immune cellular function","volume":"23","author":"Scheinberg","year":"1990","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.addr.2021.113896_b0340","doi-asserted-by":"crossref","unstructured":"S.B. Cohen, The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis, Rheum Dis Clin North Am, 30 (2004) 365-380, vii.","DOI":"10.1016\/j.rdc.2004.01.005"},{"key":"10.1016\/j.addr.2021.113896_b0345","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.addr.2021.113896_b0350","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.addr.2021.113896_b0355","first-page":"e325","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study, Lancet","volume":"2","author":"Cavalli","year":"2020","journal-title":"Rheumatol"},{"key":"10.1016\/j.addr.2021.113896_b0360","doi-asserted-by":"crossref","first-page":"e586","DOI":"10.1016\/S2665-9913(20)30273-3","article-title":"Anakinra for severe forms of COVID-19","volume":"2","author":"Khan","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.addr.2021.113896_b0365","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.addr.2021.113896_b0370","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3201\/eid1011.040367","article-title":"Women and autoimmune diseases","volume":"10","author":"Fairweather","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.addr.2021.113896_b0375","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1172\/JCI78088","article-title":"Mechanisms of human autoimmunity","volume":"125","author":"Rosenblum","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.addr.2021.113896_b0380","article-title":"Why Don't We Have a Vaccine Against Autoimmune Diseases? - A Review","volume":"10","author":"Rosenthal","year":"2019","journal-title":"J Clin Cell Immunol"},{"key":"10.1016\/j.addr.2021.113896_b0385","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrd3436","article-title":"Belimumab","volume":"10","author":"Sanz","year":"2011","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.addr.2021.113896_b0390","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1212\/CPJ.0b013e318296f299","article-title":"Teriflunomide","volume":"3","author":"Oh","year":"2013","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.addr.2021.113896_b0395","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.clinthera.2015.03.001","article-title":"New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis","volume":"37","author":"English","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.addr.2021.113896_b0400","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s40265-015-0436-4","article-title":"Eluxadoline: First Global Approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2021.113896_b0405","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12883-016-0635-y","article-title":"Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study","volume":"16","author":"Gold","year":"2016","journal-title":"BMC Neurol"},{"key":"10.1016\/j.addr.2021.113896_b0410","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.2147\/DDDT.S102141","article-title":"Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy","volume":"10","author":"Deepak","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.addr.2021.113896_b0415","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s40265-019-01211-z","article-title":"Upadacitinib: First Approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2021.113896_b0420","doi-asserted-by":"crossref","first-page":"1703531","DOI":"10.1080\/19420862.2019.1703531","article-title":"Antibodies to watch in 2020","volume":"12","author":"Kaplon","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2021.113896_b0425","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.addr.2021.113896_b0430","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-020-01319-7","article-title":"Ozanimod: First Approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2021.113896_b0435","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000464","article-title":"Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials","volume":"8","author":"Tummala","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.addr.2021.113896_b0440","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41578-020-00277-6","article-title":"Extracellular vesicles versus synthetic nanoparticles for drug delivery","volume":"6","author":"Witwer","year":"2021","journal-title":"Nature Reviews Materials"},{"key":"10.1016\/j.addr.2021.113896_b0445","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.1021\/nn503735w","article-title":"Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O6-benzylguanine to brain tumors","volume":"8","author":"Stephen","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2021.113896_b0450","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.addr.2020.06.007","article-title":"Engineering the drug carrier biointerface to overcome biological barriers to drug delivery","volume":"167","author":"Finbloom","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.addr.2021.113896_b0455","doi-asserted-by":"crossref","first-page":"12045","DOI":"10.1038\/s41598-017-11533-1","article-title":"Formation and purification of tailored liposomes for drug delivery using a module-based micro continuous-flow system","volume":"7","author":"Dimov","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.addr.2021.113896_b0460","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/jir.2018.0129","article-title":"Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9","volume":"39","author":"Skrombolas","year":"2019","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.addr.2021.113896_b0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179431","article-title":"Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy","volume":"12","author":"Charych","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.113896_b0470","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.addr.2021.113896_b0475","doi-asserted-by":"crossref","unstructured":"C.W.t. Shields, M.A. Evans, L.L. Wang, N. Baugh, S. Iyer, D. Wu, Z. Zhao, A. Pusuluri, A. Ukidve, D.C. Pan, S. Mitragotri, Cellular backpacks for macrophage immunotherapy, Sci Adv, 6 (2020) eaaz6579.","DOI":"10.1126\/sciadv.aaz6579"},{"key":"10.1016\/j.addr.2021.113896_b0480","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-1-61779-052-2_14","article-title":"Viruses as nanomaterials for drug delivery","volume":"726","author":"Lockney","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.addr.2021.113896_b0485","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3389\/fimmu.2014.00491","article-title":"Macrophage cytokines: involvement in immunity and infectious diseases","volume":"5","author":"Arango Duque","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2021.113896_b0490","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/AIA.0b013e318034194e","article-title":"Cytokines, inflammation, and pain","volume":"45","author":"Zhang","year":"2007","journal-title":"Int Anesthesiol Clin"},{"key":"10.1016\/j.addr.2021.113896_b0495","first-page":"9259646","article-title":"Biologics for Targeting Inflammatory Cytokines","volume":"2016","author":"Rider","year":"2016","journal-title":"Clinical Uses, and Limitations, Int J Cell Biol"},{"key":"10.1016\/j.addr.2021.113896_b0500","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.addr.2021.113896_b0505","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/jir.2018.0019","article-title":"Cytokines in the Treatment of Cancer","volume":"39","author":"Conlon","year":"2019","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.addr.2021.113896_b0510","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1128\/cdli.1.3.257-260.1994","article-title":"Cytokines and cytokine measurements in a clinical laboratory","volume":"1","author":"Whiteside","year":"1994","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.addr.2021.113896_b0515","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fcell.2020.00402","article-title":"Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy","volume":"8","author":"Chulpanova","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.addr.2021.113896_b0520","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028472","article-title":"Cytokines in Cancer Immunotherapy","volume":"10","author":"Waldmann","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.addr.2021.113896_b0525","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/1091581815584918","article-title":"Cytokines: The Good, the Bad, and the Deadly","volume":"34","author":"Ramani","year":"2015","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.addr.2021.113896_b0530","first-page":"212","article-title":"The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma","volume":"6","author":"Pachella","year":"2015","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0535","first-page":"11","article-title":"Managing toxicities of high-dose interleukin-2","volume":"16","author":"Schwartz","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.addr.2021.113896_b0540","doi-asserted-by":"crossref","first-page":"9056173","DOI":"10.1155\/2018\/9056173","article-title":"Prospects of IL-2 in Cancer Immunotherapy","volume":"2018","author":"Choudhry","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.addr.2021.113896_b0545","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1163462","article-title":"Role of IL-2 in cancer immunotherapy","volume":"5","author":"Jiang","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.addr.2021.113896_b0550","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.addr.2021.113896_b0555","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/j.seminoncol.2006.06.004","article-title":"Interleukin-2 therapy of metastatic renal cell carcinoma\u2013predictors of response","volume":"33","author":"McDermott","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0560","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.addr.2021.113896_b0565","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and Function of Interleukin-2 in T Lymphocytes","volume":"36","author":"Ross","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.addr.2021.113896_b0570","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.3131876","article-title":"Interleukin-2: inception, impact, and implications","volume":"240","author":"Smith","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.113896_b0575","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/ni.2030","article-title":"Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages","volume":"12","author":"Liao","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.addr.2021.113896_b0580","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1073\/pnas.0400339101","article-title":"Interleukin 2 plays a central role in Th2 differentiation","volume":"101","author":"Cote-Sierra","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.addr.2021.113896_b0585","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1073\/pnas.1301138111","article-title":"Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression","volume":"111","author":"Liao","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.addr.2021.113896_b0590","doi-asserted-by":"crossref","unstructured":"A. Laurence, C.M. Tato, T.S. Davidson, Y. Kanno, Z. Chen, Z. Yao, R.B. Blank, F. Meylan, R. Siegel, L. Hennighausen, E.M. Shevach, J. O'Shea J, Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation, Immunity, 26 (2007) 371-381.","DOI":"10.1016\/j.immuni.2007.02.009"},{"key":"10.1016\/j.addr.2021.113896_b0595","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.immuni.2012.02.012","article-title":"Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation","volume":"36","author":"Ballesteros-Tato","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2021.113896_b0600","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm866","article-title":"Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo","volume":"9","author":"Blattman","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.addr.2021.113896_b0605","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M","article-title":"Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer","volume":"83","author":"Kammula","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2021.113896_b0610","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-19-1510","article-title":"Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)","author":"Diab","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.addr.2021.113896_b0615","first-page":"711","article-title":"A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rbetagamma-Biased Cytokine","volume":"9","author":"Bentebibel","year":"2019","journal-title":"Patients with Advanced or Metastatic Solid Tumors, Cancer Discov"},{"key":"10.1016\/j.addr.2021.113896_b0620","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41467-019-12901-3","article-title":"Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist","volume":"11","author":"Parisi","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.addr.2021.113896_b0625","doi-asserted-by":"crossref","first-page":"e1277306","DOI":"10.1080\/2162402X.2016.1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines","volume":"6","author":"Klein","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.addr.2021.113896_b0630","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2326-6066.CIR-13-0206","article-title":"Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses","volume":"2","author":"Weide","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.addr.2021.113896_b0635","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1200\/JCO.2009.27.8861","article-title":"Antitumor activity of hu14.18-IL2 in patients with relapsed\/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study","volume":"28","author":"Shusterman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0640","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41586-018-0830-7","article-title":"De novo design of potent and selective mimics of IL-2 and IL-15","volume":"565","author":"Silva","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.113896_b0645","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/1097-0282(2000)55:4<254::AID-BIP1001>3.0.CO;2-1","article-title":"The human interferon alpha species and receptors","volume":"55","author":"Pestka","year":"2000","journal-title":"Biopolymers"},{"key":"10.1016\/j.addr.2021.113896_b0650","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1200\/JCO.1986.4.6.900","article-title":"Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients","volume":"4","author":"Golomb","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0655","first-page":"1608","article-title":"Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma","volume":"329","author":"Solal-Celigny","year":"1993","journal-title":"Groupe d'Etude des Lymphomes de l'Adulte, N Engl J Med"},{"key":"10.1016\/j.addr.2021.113896_b0660","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0665","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7326\/0003-4819-100-5-671","article-title":"Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome","volume":"100","author":"Groopman","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.addr.2021.113896_b0670","doi-asserted-by":"crossref","unstructured":"T.M. Herndon, S.G. Demko, X. Jiang, K. He, J.E. Gootenberg, M.H. Cohen, P. Keegan, R. Pazdur, U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma, Oncologist, 17 (2012) 1323-1328.","DOI":"10.1634\/theoncologist.2012-0123"},{"key":"10.1016\/j.addr.2021.113896_b0675","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/0008-5472.CAN-17-1980","article-title":"Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments","volume":"78","author":"Cauwels","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.addr.2021.113896_b0680","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/hep.24306","article-title":"Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties","volume":"53","author":"Fioravanti","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.addr.2021.113896_b0685","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2021.113896_b0690","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1158\/1078-0432.CCR-04-0540","article-title":"Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease","volume":"10","author":"Younes","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2021.113896_b0695","first-page":"75","article-title":"Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma","volume":"4","author":"Bajetta","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2021.113896_b0700","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00002371-200307000-00006","article-title":"Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder","volume":"26","author":"Weiss","year":"2003","journal-title":"J Immunother"},{"key":"10.1016\/j.addr.2021.113896_b0705","doi-asserted-by":"crossref","first-page":"575597","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized Interleukin-12 for Cancer Immunotherapy","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2021.113896_b0710","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jconrel.2019.12.035","article-title":"Single injection of IL-12 coacervate as an effective therapy against B16\u2013F10 melanoma in mice","volume":"318","author":"Hwang","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2021.113896_b0715","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw2614","article-title":"Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy","volume":"11","author":"Momin","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.addr.2021.113896_b0720","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/s43018-020-0095-6","article-title":"Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity","volume":"1","author":"Li","year":"2020","journal-title":"Nature Cancer"},{"key":"10.1016\/j.addr.2021.113896_b0725","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.annonc.2019.12.008","article-title":"Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients","volume":"31","author":"Algazi","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0730","first-page":"3259","article-title":"Anti-colorectal cancer effect of interleukin-2 and interferon-beta fusion gene driven by carcinoembryonic antigen promoter","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.addr.2021.113896_b0735","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/1535370220905047","article-title":"Hyperthermic intraperitoneal chemotherapy with recombinant mutant human TNF-alpha and raltitrexed in mice with colorectal-peritoneal carcinomatosis","volume":"245","author":"Gong","year":"2020","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.addr.2021.113896_b0740","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1186\/s12885-018-5193-9","article-title":"A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma","volume":"18","author":"McQuade","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.addr.2021.113896_b0745","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000668","article-title":"Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma","volume":"8","author":"Borch","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2021.113896_b0750","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-014-0080-6","article-title":"Immunosuppressive\/anti-inflammatory cytokines directly and indirectly inhibit endothelial dysfunction\u2013a novel mechanism for maintaining vascular function","volume":"7","author":"Shao","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0755","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in Inflammatory Disease","volume":"20","author":"Kany","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.addr.2021.113896_b0760","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1172\/JCI119806","article-title":"Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand","volume":"100","author":"Georgescu","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.addr.2021.113896_b0765","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1038\/s41598-019-43530-x","article-title":"Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Mahmoudpour","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.addr.2021.113896_b0770","first-page":"1","article-title":"Multiple Sclerosis: Pathogenesis","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Symptoms, Diagnoses and Cell-Based Therapy, Cell J"},{"key":"10.1016\/j.addr.2021.113896_b0775","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1474-4422(14)70305-9","article-title":"Role of the innate and adaptive immune responses in the course of multiple sclerosis","volume":"14","author":"Hemmer","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.addr.2021.113896_b0780","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(16)31320-4","article-title":"Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function","volume":"389","author":"Ontaneda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.113896_b0785","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ebiom.2019.09.059","article-title":"Interferon-beta corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection","volume":"49","author":"Feng","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2021.113896_b0790","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.addr.2021.113896_b0795","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94296","article-title":"Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer","volume":"2","author":"Dominguez","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.addr.2021.113896_b0800","doi-asserted-by":"crossref","first-page":"e90353","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma","volume":"9","author":"Morris","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.113896_b0805","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","article-title":"A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance non-small cell lung cancer patients","volume":"68","author":"Jatoi","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.addr.2021.113896_b0810","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0815","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: a look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0820","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2012.44.9694","article-title":"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"31","author":"Hurvitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0825","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0830","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2021.113896_b0835","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2021.113896_b0840","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","article-title":"The Intriguing History of Cancer Immunotherapy","volume":"10","author":"Dobosz","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2021.113896_b0845","doi-asserted-by":"crossref","first-page":"109821","DOI":"10.1016\/j.biopha.2020.109821","article-title":"Cancer immunotherapy: Pros, cons and beyond","volume":"124","author":"Tan","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.addr.2021.113896_b0850","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1186\/s12885-018-5020-3","article-title":"The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer)","volume":"18","author":"Guo","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.addr.2021.113896_b0855","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/jcph.591","article-title":"Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy","volume":"56","author":"Lee","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.addr.2021.113896_b0860","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2174\/156800961506150805145120","article-title":"Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety","volume":"15","author":"Azoury","year":"2015","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.addr.2021.113896_b0865","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejca.2017.09.032","article-title":"Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma","volume":"86","author":"Geoerger","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.addr.2021.113896_b0870","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0875","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41467-019-14218-7","article-title":"Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1","volume":"11","author":"Imbert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.addr.2021.113896_b0880","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2010.28.3994","article-title":"Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer","volume":"28","author":"Chung","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.addr.2021.113896_b0885","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001895","article-title":"Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2021.113896_b0890","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ijc.31301","article-title":"Correlation between sex and efficacy of immune checkpoint inhibitors","volume":"143","author":"Wu","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.addr.2021.113896_b0895","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/annrheumdis-2016-209668","article-title":"Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial","volume":"76","author":"Wallace","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.addr.2021.113896_b0900","unstructured":"P.E. Lipsky, D.M. van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, J.R. Kalden, J.S. Smolen, M. Weisman, P. Emery, M. Feldmann, G.R. Harriman, R.N. Maini, G. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study, Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group, N Engl J Med, 343 (2000) 1594-1602."},{"key":"10.1016\/j.addr.2021.113896_b0905","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.addr.2021.113896_b0910","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2021.113896_b0915","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1080\/13696998.2017.1355310","article-title":"Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis","volume":"20","author":"Yang","year":"2017","journal-title":"J Med Econ"},{"key":"10.1016\/j.addr.2021.113896_b0920","doi-asserted-by":"crossref","first-page":"S33.004","DOI":"10.1212\/WNL.88.16_supplement.S33.004","article-title":"Efficacy Results from the Phase 2b SYNERGY Study: Treatment of Disabling Multiple Sclerosis with the Anti-LINGO-1 Monoclonal Antibody Opicinumab (S33.004)","volume":"88","author":"Mellion","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2021.113896_b0925","doi-asserted-by":"crossref","unstructured":"S.V. Navarra, R.M. Guzman, A.E. Gallacher, S. Hall, R.A. Levy, R.E. Jimenez, E.K. Li, M. Thomas, H.Y. Kim, M.G. Leon, C. Tanasescu, E. Nasonov, J.L. Lan, L. Pineda, Z.J. Zhong, W. Freimuth, M.A. Petri, B.-S. Group, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, Lancet, 377 (2011) 721-731.","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"10.1016\/j.addr.2021.113896_b0930","doi-asserted-by":"crossref","unstructured":"R. Furie, M. Petri, O. Zamani, R. Cervera, D.J. Wallace, D. Tegzova, J. Sanchez-Guerrero, A. Schwarting, J.T. Merrill, W.W. Chatham, W. Stohl, E.M. Ginzler, D.R. Hough, Z.J. Zhong, W. Freimuth, R.F. van Vollenhoven, B.-S. Group, A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, Arthritis Rheum, 63 (2011) 3918-3930.","DOI":"10.1002\/art.30613"},{"key":"10.1016\/j.addr.2021.113896_b0935","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2021.113896_b0940","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.addr.2021.113896_b0945","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma","volume":"18","author":"Bommareddy","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.addr.2021.113896_b0950","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","article-title":"Talimogene laherparepvec: First in class oncolytic virotherapy","volume":"14","author":"Conry","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.addr.2021.113896_b0955","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1586\/14737140.2015.1115725","article-title":"Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy","volume":"15","author":"Harrington","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.addr.2021.113896_b0960","doi-asserted-by":"crossref","first-page":"19976","DOI":"10.18632\/oncotarget.5116","article-title":"Going viral: a review of replication-selective oncolytic adenoviruses","volume":"6","author":"Larson","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2021.113896_b0965","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.addr.2021.113896_b0970","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1007\/s11033-013-2638-8","article-title":"Cancer targeting gene-viro-therapy for pancreatic cancer using oncolytic adenovirus ZD55-IL-24 in immune-competent mice","volume":"40","author":"He","year":"2013","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.addr.2021.113896_b0975","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41467-017-02205-9","article-title":"Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.addr.2021.113896_b0980","article-title":"Targeting the extracellular matrix for immunomodulation: applications in drug delivery and cell therapies, Drug Deliv","author":"Aghlara-Fotovat","year":"2021","journal-title":"Transl Res"},{"key":"10.1016\/j.addr.2021.113896_b0985","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","article-title":"The application of CAR-T cell therapy in hematological malignancies: advantages and challenges","volume":"8","author":"Zhao","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.addr.2021.113896_b0990","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/0963689719837897","article-title":"The Pros and Cons of Mesenchymal Stem Cell-Based Therapies","volume":"28","author":"Musial-Wysocka","year":"2019","journal-title":"Cell Transplant"},{"key":"10.1016\/j.addr.2021.113896_b0995","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fbioe.2019.00043","article-title":"Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology","volume":"7","author":"Caliendo","year":"2019","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.addr.2021.113896_b1000","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.addr.2021.113896_b1005","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1089\/hum.2015.054","article-title":"CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma","volume":"26","author":"Enblad","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.addr.2021.113896_b1010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.addr.2021.113896_b1015","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: Design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.addr.2021.113896_b1020","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-021-00175-8","article-title":"Industrializing engineered autologous T cells as medicines for solid tumours","author":"Britten","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.addr.2021.113896_b1025","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2021.113896_b1030","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2021.113896_b1035","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A Phase I\/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2021.113896_b1040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13045-020-00953-8","article-title":"Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia","volume":"13","author":"Gu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.addr.2021.113896_b1045","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040873","article-title":"IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells","volume":"9","author":"Hombach","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.addr.2021.113896_b1050","doi-asserted-by":"crossref","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2021.113896_b1055","doi-asserted-by":"crossref","DOI":"10.1038\/s41434-021-00246-w","article-title":"Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany","author":"Albinger","year":"2021","journal-title":"Gene Ther"},{"key":"10.1016\/j.addr.2021.113896_b1060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.canlet.2019.11.033","article-title":"CAR-NK for tumor immunotherapy: Clinical transformation and future prospects","volume":"472","author":"Wang","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.addr.2021.113896_b1065","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1002\/cti2.1250","article-title":"Natural killer cells in inflammatory autoimmune diseases","volume":"10","author":"Yang","year":"2021","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.addr.2021.113896_b1070","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/ijc.32269","article-title":"Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth","volume":"145","author":"Oelsner","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.addr.2021.113896_b1075","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2021.113896_b1080","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2021.113896_b1085","first-page":"2456","article-title":"Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma","volume":"9","author":"Yang","year":"2019","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.addr.2021.113896_b1090","doi-asserted-by":"crossref","first-page":"117580","DOI":"10.1016\/j.lfs.2020.117580","article-title":"Dendritic cell therapy in cancer treatment; the state-of-the-art","volume":"254","author":"Sadeghzadeh","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.addr.2021.113896_b1095","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2021.113896_b1100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071338","article-title":"Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies","volume":"18","author":"Adamska","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.addr.2021.113896_b1105","first-page":"829","article-title":"Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial","volume":"60","author":"Lodge","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.addr.2021.113896_b1110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.addr.2021.113896_b1115","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3892\/or.2012.1956","article-title":"Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial","volume":"28","author":"Oshita","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.addr.2021.113896_b1120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12967-018-1507-6","article-title":"First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma","volume":"16","author":"Liau","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.addr.2021.113896_b1125","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fimmu.2018.00350","article-title":"Mechanisms of Tolerance Induction by Dendritic Cells In Vivo","volume":"9","author":"Hasegawa","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2021.113896_b1130","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1084\/jem.20082394","article-title":"Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity","volume":"206","author":"Ohnmacht","year":"2009","journal-title":"J Exp Med"},{"issue":"Suppl 1","key":"10.1016\/j.addr.2021.113896_b1135","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar2414","article-title":"T-cell co-stimulatory pathways in autoimmunity","volume":"10","author":"Goronzy","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.addr.2021.113896_b1140","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2567.2010.03396.x","article-title":"Tolerogenic dendritic cells and their potential applications","volume":"132","author":"Hu","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2021.113896_b1145","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","article-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2021.113896_b1150","doi-asserted-by":"crossref","first-page":"390","DOI":"10.5114\/ceji.2017.72807","article-title":"The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis","volume":"42","author":"Kurowska","year":"2017","journal-title":"Cent Eur J Immunol"},{"key":"10.1016\/j.addr.2021.113896_b1155","doi-asserted-by":"crossref","first-page":"290ra287","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.addr.2021.113896_b1160","doi-asserted-by":"crossref","unstructured":"B. Willekens, S. Presas-Rodriguez, M.J. Mansilla, J. Derdelinckx, W.P. Lee, G. Nijs, M. De Laere, I. Wens, P. Cras, P. Parizel, W. Van Hecke, A. Ribbens, T. Billiet, G. Adams, M.M. Couttenye, J. Navarro-Barriuso, A. Teniente-Serra, B. Quirant-Sanchez, A. Lopez-Diaz de Cerio, S. Inoges, F. Prosper, A. Kip, H. Verheij, C.C. Gross, H. Wiendl, M.S. Van Ham, A. Ten Brinke, A.M. Barriocanal, A. Massuet-Vilamajo, N. Hens, Z. Berneman, E. Martinez-Caceres, N. Cools, C. Ramo-Tello, R. consortium, Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration, BMJ Open, 9 (2019) e030309.","DOI":"10.1136\/bmjopen-2019-030309"},{"key":"10.1016\/j.addr.2021.113896_b1165","doi-asserted-by":"crossref","first-page":"5392623","DOI":"10.1155\/2016\/5392623","article-title":"Immunomodulatory Effects of 1,25-Dihydroxyvitamin D3 on Dendritic Cells Promote Induction of T Cell Hyporesponsiveness to Myelin-Derived Antigens","volume":"2016","author":"Lee","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.addr.2021.113896_b1170","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/eji.201141835","article-title":"Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients","volume":"42","author":"Raiotach-Regue","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.addr.2021.113896_b1175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1479-5876-9-89","article-title":"Comparative study of clinical grade human tolerogenic dendritic cells","volume":"9","author":"Naranjo-Gomez","year":"2011","journal-title":"J Transl Med"},{"key":"10.1016\/j.addr.2021.113896_b1180","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3389\/fimmu.2017.01279","article-title":"Clinical Tolerogenic Dendritic Cells: Exploring Therapeutic Impact on Human Autoimmune Disease","volume":"8","author":"Phillips","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2021.113896_b1185","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.4049\/jimmunol.178.12.7503","article-title":"The innate immune system in allograft rejection and tolerance","volume":"178","author":"LaRosa","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.addr.2021.113896_b1190","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.it.2016.09.003","article-title":"Antigen Presentation in Transplantation","volume":"37","author":"Alegre","year":"2016","journal-title":"Trends Immunol"},{"key":"10.1016\/j.addr.2021.113896_b1195","doi-asserted-by":"crossref","unstructured":"A.J. Matas, R. Kandaswamy, A. Humar, W.D. Payne, D.L. Dunn, J.S. Najarian, R.W. Gruessner, K.J. Gillingham, L.E. McHugh, D.E. Sutherland, Long-term immunosuppression, without maintenance prednisone, after kidney transplantation, Ann Surg, 240 (2004) 510-516; discussion 516-517.","DOI":"10.1097\/01.sla.0000137140.79206.d0"},{"key":"10.1016\/j.addr.2021.113896_b1200","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fimmu.2016.00015","article-title":"Prospective Clinical Testing of Regulatory Dendritic Cells in Organ Transplantation","volume":"7","author":"Thomson","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2021.113896_b1205","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2021.113896_b1210","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jconrel.2019.12.053","article-title":"Relaxin-FOLFOX-IL-12 triple combination therapy engages memory response and achieves long-term survival in colorectal cancer liver metastasis","volume":"319","author":"Hu","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2021.113896_b1215","article-title":"Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets, Nat","author":"Hu","year":"2021","journal-title":"Biomed Eng"},{"key":"10.1016\/j.addr.2021.113896_b1220","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","article-title":"Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial","volume":"27","author":"Montfort","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2021.113896_b1225","unstructured":"U.S. Food & Drug Administration, Development & Approval Process | Drugs, 2019."},{"key":"10.1016\/j.addr.2021.113896_b1230","unstructured":"U.s. Food & Drug Administration, Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products, 1995."},{"key":"10.1016\/j.addr.2021.113896_b1235","doi-asserted-by":"crossref","unstructured":"J.L. Benci, L.R. Johnson, R. Choa, Y. Xu, J. Qiu, Z. Zhou, B. Xu, D. Ye, K.L. Nathanson, C.H. June, E.J. Wherry, N.R. Zhang, H. Ishwaran, M.D. Hellmann, J.D. Wolchok, T. Kambayashi, A.J. Minn, Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade, Cell, 178 (2019) 933-948 e914.","DOI":"10.1016\/j.cell.2019.07.019"},{"key":"10.1016\/j.addr.2021.113896_b1240","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/PPO.0b013e3181eb3393","article-title":"Interface of signal transduction inhibition and immunotherapy in melanoma","volume":"16","author":"Shada","year":"2010","journal-title":"Cancer J"},{"key":"10.1016\/j.addr.2021.113896_b1245","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/08830180701365941","article-title":"Targeting costimulatory pathways for tumor immunotherapy","volume":"26","author":"Ward","year":"2007","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.addr.2021.113896_b1250","first-page":"114","article-title":"Lost in translation: animal models and clinical trials in cancer treatment","volume":"6","author":"Mak","year":"2014","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.addr.2021.113896_b1255","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/annonc\/mdw041","article-title":"Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies","volume":"27","author":"Sanmamed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.addr.2021.113896_b1260","unstructured":"U.S. Food & Drug Administration, SOPP 8214: INTERACT Meetings with Sponsors for Drugs and Biological Products, (2020)."},{"key":"10.1016\/j.addr.2021.113896_b1265","unstructured":"U.S. Food & Drug Administration, Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Guidance for Industry, 2017."},{"key":"10.1016\/j.addr.2021.113896_b1270","unstructured":"U.S. Food & Drug Administration, Requesting FDA Feedback on Combination Products Guidance for Industry and FDA Staff, 2020."},{"key":"10.1016\/j.addr.2021.113896_b1275","unstructured":"U.S. Food & Drug Administration, Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics Guidance for Industry, 2020."},{"key":"10.1016\/j.addr.2021.113896_b1280","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s11095-011-0523-5","article-title":"Immunogenicity of therapeutic proteins: the use of animal models","volume":"28","author":"Brinks","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.addr.2021.113896_b1285","first-page":"24","article-title":"Defining the difference: What Makes Biologics Unique","volume":"1","author":"Morrow","year":"2004","journal-title":"Biotechnol Healthc"},{"key":"10.1016\/j.addr.2021.113896_b1290","unstructured":"R. Haddock, S. Lin-Gibson, N. Lumelsky, R. McFarland, K. Roy, K. Saha, J. Zhang, and C. Zylberberg., Manufacturing Cell Therapies: The Paradigm Shift in Health Care of this Century. NAM Perspectives. Discussion Paper. National Academy of Medicine, Washington, DC., 2017"},{"key":"10.1016\/j.addr.2021.113896_b1295","unstructured":"U.S. Food & Drug Administration, Q5E Comparability of Biotechnological\/Biological Products Subject to Changes in Their Manufacturing Process, 2020."},{"key":"10.1016\/j.addr.2021.113896_b1300","first-page":"639","article-title":"Prediction of response in cancer immunotherapy","volume":"31","author":"Characiejus","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.addr.2021.113896_b1305","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2217\/imt.10.76","article-title":"Monitoring cytokine profiles during immunotherapy","volume":"2","author":"Siebert","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.addr.2021.113896_b1310","unstructured":"U.S. Food & Drug Administration, Immunogenicity Assessment for Therapeutic Protein Products, 2018."},{"key":"10.1016\/j.addr.2021.113896_b1315","doi-asserted-by":"crossref","first-page":"112764","DOI":"10.1016\/j.jim.2020.112764","article-title":"Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies","volume":"479","author":"Bharadwaj","year":"2020","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.addr.2021.113896_b1320","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3389\/fimmu.2020.01527","article-title":"Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNbeta","volume":"11","author":"Waddington","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2021.113896_b1325","unstructured":"U.S. Food & Drug Administration, Best Practices for Communication Between IND Sponsors and FDA During Drug Development: Guidance for Industry and Review Staff, 2017."},{"key":"10.1016\/j.addr.2021.113896_b1330","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"10.1016\/j.addr.2021.113896_b1335","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: New estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J Health Econ"},{"key":"10.1016\/j.addr.2021.113896_b1340","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009\u20132018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2021.113896_b1345","unstructured":"U.S. Food & Drug Administration, Expedited Programs for Serious Conditions \u2013 Drugs and Biologics, 2020."},{"key":"10.1016\/j.addr.2021.113896_b1350","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/blr.2015.9999","article-title":"FDA's Expedited Approval Mechanisms for New Drug Products","volume":"34","author":"Kepplinger","year":"2015","journal-title":"Biotechnol Law Rep"},{"key":"10.1016\/j.addr.2021.113896_b1355","unstructured":"U.S. Food & Drug Administration, Accelerated Approval, 2018."},{"key":"10.1016\/j.addr.2021.113896_b1360","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13027-020-00338-z","article-title":"FDA efficiency for approval process of COVID-19 therapeutics","volume":"15","author":"Cassidy","year":"2020","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.addr.2021.113896_b1365","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/14737159.2016.1239530","article-title":"Advances in diagnostics for transplant rejection","volume":"16","author":"Nasr","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.addr.2021.113896_b1370","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic barriers to cancer immunotherapy","author":"DePeaux","year":"2021","journal-title":"Nature Reviews Immunology"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21002891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21002891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:10:47Z","timestamp":1759209047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X21002891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":274,"alternative-id":["S0169409X21002891"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2021.113896","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical translation of immunomodulatory therapeutics","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2021.113896","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113896"}}